INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction): Rationale and Design

Circulation: Heart Failure

Volumn 10, Issue 5, 2017, Pages

  Reddy, Yogesh N V ^a   Lewis, Gregory D ^b   Shah, Sanjiv J ^c   LeWinter, Martin ^d   Semigran, Marc ^b   Davila Roman, Victor G ^e   Anstrom, Kevin ^f   Hernandez, Adrian ^f   Braunwald, Eugene ^g   Redfield, Margaret M ^a   Borlaug, Barry A ^a  

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

clinical trial; exercise; heart failure; heart failure with preserved ejection fraction; metabolism; nitric oxide

Indexed keywords

CYSTATIN C; METHEMOGLOBIN; SODIUM NITRITE; NITRIC ACID DERIVATIVE;

ACCELEROMETRY; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EXERCISE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; DRUG EFFECTS; EXERCISE TEST; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EXERCISE TEST; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; NITRATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 85019547346     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.003862     Document Type: Article

References (65)

1. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134:73-90. doi: 10.1161/CIRCULATIONAHA.116.021884.
2. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092.
3. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507-515. doi: 10.1038/nrcardio.2014.83.
4. Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol. 2015;12:294-304. doi: 10.11909/j. issn.1671-5411.2015.03.013.
5. Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular- pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016;37:3293-3302. doi: 10.1093/eurheartj/ehw241.
6. Santos M, Opotowsky AR, Shah AM, Tracy J, Waxman AB, Systrom DM. Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction. Circ Heart Fail. 2015;8:278-285. doi: 10.1161/CIRCHEARTFAILURE.114.001551.
7. Abudiab MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, Borlaug BA. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15:776-785. doi: 10.1093/eurjhf/hft026.
8. Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2015;66:1672-1682. doi: 10.1016/j.jacc.2015.07.067.
9. Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams- Huet B, Pacini EL, Shibata S, Palmer MD, Newcomer BR, Levine BD. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:1296-1304. doi: 10.1093/eurjhf/hfr133.
10. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, Houstis NE, Eisman AS, Hough SS, Lewis GD. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8:286-294. doi: 10.1161/CIRCHEARTFAILURE.114.001825.
11. Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58:265-274. doi: 10.1016/j.jacc.2011.02.055.
12. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-595. doi: 10.1161/CIRCHEARTFAILURE.109.930701.
13. Borlaug BA, Melenovsky V, Koepp KE. Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction. Circ Res. 2016;119:880-886. doi: 10.1161/CIRCRESAHA.116.309184.
14. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935-944. doi: 10.1161/CIRCHEARTFAILURE.113.001229.
15. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol. 2010;56:855-863. doi: 10.1016/j.jacc.2010.04.040.
16. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845-854. doi: 10.1016/j.jacc.2010.03.077.
17. Greene SJ, Gheorghiade M, Borlaug BA, Pieske B, Vaduganathan M, Burnett JC Jr, Roessig L, Stasch JP, Solomon SD, Paulus WJ, Butler J. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc. 2013;2:e000536. doi: 10.1161/JAHA.113.000536.
18. Reddy YN, Borlaug BA. Heart failure with preserved ejection fraction. Curr Probl Cardiol. 2016;41:145-188. doi: 10.1016/j. cpcardiol.2015.12.002.
19. Farrero M, Blanco I, Batlle M, Santiago E, Cardona M, Vidal B, Castel MA, Sitges M, Barbera JA, Perez-Villa F. Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:791-798. doi: 10.1161/CIRCHEARTFAILURE.113.000942.
20. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452-3462. doi: 10.1093/eurheartj/ehu193.
21. Mohammed SF, Hussain I, AbouEzzeddine OF, Abou Ezzeddine OF, Takahama H, Kwon SH, Forfia P, Roger VL, Redfield MM. Right ventricular function in heart failure with preserved ejection fraction: a community- based study. Circulation. 2014;130:2310-2320. doi: 10.1161/CIRCULATIONAHA.113.008461.
22. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839. doi: 10.1161/CIRCULATIONAHA.111.076075.
23. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:312-324. doi: 10.1016/j.jchf.2015.10.007.
24. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011;124:2882-2891. doi: 10.1161/CIRCULATIONAHA.111.048520.
25. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247-1259. doi: 10.1161/CIRCULATIONAHA.114.013215.
26. Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18:103-112.
27. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550-559. doi: 10.1161/CIRCULATIONAHA.114.009625.
28. van Empel VP, Mariani J, Borlaug BA, Kaye DM. Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc. 2014;3:e001293. doi: 10.1161/JAHA.114.001293.
29. Srivaratharajah K, Coutinho T, deKemp R, Liu P, Haddad H, Stadnick E, Davies RA, Chih S, Dwivedi G, Guo A, Wells GA, Bernick J, Beanlands R, Mielniczuk LM. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail. 2016;9:e002562. doi: 10.1161/CIRCHEARTFAILURE.115.002562.
30. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase- 5 inhibition in a 1-year study. Circulation. 2011;124:164-174. doi: 10.1161/CIRCULATIONAHA.110.983866.
31. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. doi: 10.1001/jama.2013.2024.
32. Borlaug BA, Lewis GD, McNulty SE, Semigran MJ, LeWinter M, Chen H, Lin G, Deswal A, Margulies KB, Redfield MM. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail. 2015;8:533-541. doi: 10.1161/CIRCHEARTFAILURE.114.001915.
33. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36:2565-2573. doi: 10.1093/eurheartj/ehv336.
34. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-451. doi: 10.1016/j. jacc.2011.09.062.
35. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015;373:2314-2324. doi: 10.1056/NEJMoa1510774.
36. Vanderpool R, Gladwin MT. Harnessing the nitrate-nitrite-nitric oxide pathway for therapy of heart failure with preserved ejection fraction. Circulation. 2015;131:334-336. doi: 10.1161/CIRCULATIONAHA.114.014149.
37. Omar SA, Webb AJ, Lundberg JO, Weitzberg E. Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases. J Intern Med. 2016;279:315-336. doi: 10.1111/joim.12441.
38. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156-167. doi: 10.1038/nrd2466.
39. Paulus WJ, van Heerebeek L. Ancient gunpowder and novel insights team up against heart failure with preserved ejection fraction. J Am Coll Cardiol. 2015;66:1683-1686. doi: 10.1016/j.jacc.2015.08.028.
40. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO 3rd, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498-1505. doi: 10.1038/nm954.
41. Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebocontrolled study. Hypertension. 2015;65:320-327. doi: 10.1161/HYPERTENSIONAHA.114.04675.
42. Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, Arghandawi S, Pearl V, Benjamin N, Loukogeorgakis S, Macallister R, Hobbs AJ, Webb AJ, Ahluwalia A. Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension. 2010;56:274-281. doi: 10.1161/HYPERTENSIONAHA. 110.153536.
43. Rammos C, Hendgen-Cotta UB, Sobierajski J, Bernard A, Kelm M, Rassaf T. Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk. J Am Coll Cardiol. 2014;63:1584-1585. doi: 10.1016/j.jacc.2013.08.691.
44. Omar SA, Fok H, Tilgner KD, Nair A, Hunt J, Jiang B, Taylor P, Chowienczyk P, Webb AJ. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. Circulation. 2015;131:381- 9; discussion 389. doi: 10.1161/CIRCULATIONAHA.114.009554.
45. DeVan AE, Johnson LC, Brooks FA, Evans TD, Justice JN, Cruickshank- Quinn C, Reisdorph N, Bryan NS, McQueen MB, Santos-Parker JR, Chonchol MB, Bassett CJ, Sindler AL, Giordano T, Seals DR. Effects of sodium nitrite supplementation on vascular function and related small metabolite signatures in middle-aged and older adults. J Appl Physiol (1985). 2016;120:416-425. doi: 10.1152/japplphysiol.00879.2015.
46. Glean AA, Ferguson SK, Holdsworth CT, Colburn TD, Wright JL, Fees AJ, Hageman KS, Poole DC, Musch TI. Effects of nitrite infusion on skeletal muscle vascular control during exercise in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2015;309:H1354-H1360. doi: 10.1152/ajpheart.00421.2015.
47. Colburn TD, Ferguson SK, Holdsworth CT, Craig JC, Musch TI, Poole DC. Effect of sodium nitrite on local control of contracting skeletal muscle microvascular oxygen pressure in healthy rats. J Appl Physiol (1985). 2017;122:153-160. doi: 10.1152/japplphysiol.00367.2016.
48. Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO, Weitzberg E. Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell Metab. 2011;13:149-159. doi: 10.1016/j. cmet.2011.01.004.
49. Lai YC, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA, St Croix CM, Garcia-Ocaña A, Goncharova EA, Tofovic SP, Mora AL, Gladwin MT. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation. 2016;133:717-731. doi: 10.1161/CIRCULATIONAHA.115.018935.
50. Coggan AR, Leibowitz JL, Spearie CA, Kadkhodayan A, Thomas DP, Ramamurthy S, Mahmood K, Park S, Waller S, Farmer M, Peterson LR. Acute dietary nitrate intake improves muscle contractile function in patients with heart failure: A Double-Blind, Placebo-Controlled, Randomized Trial. Circ Heart Fail. 2015;8:914-920. doi: 10.1161/CIRCHEARTFAILURE.115.002141.
51. Bhushan S, Kondo K, Polhemus DJ, Otsuka H, Nicholson CK, Tao YX, Huang H, Georgiopoulou VV, Murohara T, Calvert JW, Butler J, Lefer DJ. Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling. Circ Res. 2014;114:1281-1291. doi: 10.1161/CIRCRESAHA.114.301475.
52. Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, Bauer PM, Choi JJ, Curtis E, Choi AM, Gladwin MT. Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation. 2010;121:98-109. doi: 10.1161/CIRCULATIONAHA.109.891077.
53. Ormerod JO, Arif S, Mukadam M, Evans JD, Beadle R, Fernandez BO, Bonser RS, Feelisch M, Madhani M, Frenneaux MP. Short-term intravenous sodium nitrite infusion improves cardiac and pulmonary hemodynamics in heart failure patients. Circ Heart Fail. 2015;8:565-571. doi: 10.1161/CIRCHEARTFAILURE.114.001716.
54. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015;131:371-80; discussion 380. doi: 10.1161/CIRCULATIONAHA.114.012957.
55. Eggebeen J, Kim-Shapiro DB, Haykowsky M, Morgan TM, Basu S, Brubaker P, Rejeski J, Kitzman DW. One week of daily dosing with beetroot juice improves submaximal endurance and blood pressure in older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2016;4:428-437. doi: 10.1016/j.jchf.2015.12.013.
56. Zamani P, Tan V, Soto-Calderon H, Beraun M, Brandimarto JA, Trieu L, Varakantam S, Doulias PT, Townsend RR, Chittams J, Margulies KB, Cappola TP, Poole DC, Ischiropoulos H, Chirinos JA. Pharmacokinetics and pharmacodynamics of inorganic nitrate in heart failure with preserved ejection fraction. Circ Res. 2017;120:1151-1161. doi: 10.1161/CIRCRESAHA.116.309832.
57. Simon MA, Vanderpool RR, Nouraie M, Bachman TN, White PM, Sugahara M, Gorcsan J 3rd, Parsley EL, Gladwin MT. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight. 2016;1:e89620. doi: 10.1172/jci.insight.89620.
58. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4:23-36. doi: 10.1016/j.hfc.2007.10.001.
59. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, Oldfield EH, Cannon RO 3rd, Schechter AN, Gladwin MT. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007;116:1821-1831. doi: 10.1161/CIRCULATIONAHA.107.712133.
60. Oelze M, Knorr M, Kröller-Schön S, Kossmann S, Gottschlich A, Rümmler R, Schuff A, Daub S, Doppler C, Kleinert H, Gori T, Daiber A, Münzel T. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J. 2013;34:3206-3216. doi: 10.1093/eurheartj/ehs100.
61. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49:1289-1295. doi: 10.1016/j.jacc.2006.10.074.
62. Fletcher GF, Balady G, Froelicher VF, Hartley LH, Haskell WL, Pollock ML. Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1995;91:580-615.
63. Rix PJ, Vick A, Attkins NJ, Barker GE, Bott AW, Alcorn H Jr, Gladwin MT, Shiva S, Bradley S, Hussaini A, Hoye WL, Parsley EL, Masamune H. Pharmacokinetics, pharmacodynamics, safety, and tolerability of nebulized sodium nitrite (AIR001) following repeat-dose inhalation in healthy subjects. Clin Pharmacokinet. 2015;54:261-272. doi: 10.1007/s40262-014-0201-y.
64. Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, Dávila-Román VG, Mann DL, Spertus JA. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail. 2013;6:1139-1146. doi: 10.1161/CIRCHEARTFAILURE.113.000359.
65. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O'Connor CM, Weinfurt KP; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1451-1459. doi: 10.1001/jama.2009.457.